Responses
Clinical/translational cancer immunotherapy
Original research
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
Compose a Response to This Article
Other responses
No responses have been published for this article.
